Polatuzumab Vedotin-Piiq 140 Milligram Intravenous Solution Priced at $594.62 at Aurora Sheboygan, Wisconsin

Polatuzumab Vedotin-Piiq is an advanced targeted cancer therapy primarily used for certain types of non-Hodgkin lymphoma. It works by delivering cytotoxic chemotherapy directly to cancer cells while minimizing impact on healthy tissue. The listed fee of $594.62 at Aurora Medical Center in Sheboygan County covers the 140 mg intravenous medication itself but does not include costs for administration, facility fees, laboratory tests, or physician services. Patients are encouraged to request a detailed, itemized cost estimate from their provider to clarify the full scope of expenses, and to consult their insurance for coverage specifics.

Cost Breakdown

• Drug cost (140 mg dose): $594.62
• Not included: Infusion administration fee, facility charge, pre-medication, lab monitoring, physician consults, post-treatment observation

Associated Costs

• IV infusion administration (nursing and equipment)
• Clinical monitoring (vital signs, labs)
• Supportive medications (anti-nausea, steroids, etc.)
• Follow-up visits and imaging as required

Insurance & Payment Advice

• Verify with your insurance provider whether Polatuzumab Vedotin-Piiq and associated services are covered, and if prior authorization is required.
• Ask about co-pays, deductibles, and out-of-pocket maximums for both the drug and its administration.
• Explore financial assistance or manufacturer copay programs if cost is a concern.

Side-Effect Considerations & Recovery Tips

• Common side effects include fatigue, nausea, diarrhea, and low blood counts.
• Serious risks can include nerve damage (neuropathy) and infusion reactions—report symptoms promptly.
• Stay hydrated and follow your care team’s instructions to manage symptoms.
• Arrange for transportation and support, as fatigue may occur after infusions.

Frequently Asked Questions

• What is Polatuzumab Vedotin-Piiq used for?
  It is used to treat certain types of non-Hodgkin lymphoma, targeting cancer cells while sparing healthy ones, and is often combined with other chemotherapy drugs.
• What does the $594.62 fee cover?
  This fee covers only the 140 mg dose of the medication itself; additional costs for administration, monitoring, and supportive care are not included.
• How is the medication administered?
  Polatuzumab Vedotin-Piiq is given as an intravenous (IV) infusion in a clinical setting under medical supervision.
• Will insurance cover this medication?
  Coverage varies; contact your insurer to confirm if the medication and associated services are included in your plan and to check for pre-authorization requirements.
• Are there programs to help pay for this treatment?
  Some drug manufacturers and cancer organizations offer financial assistance or copay programs—ask your provider or social worker for information.
• What are the common side effects?
  Fatigue, nausea, diarrhea, and low blood cell counts are common; more serious side effects include nerve damage and infusion-related reactions.
• How often will I need to receive this medication?
  The frequency depends on your treatment plan, but Polatuzumab Vedotin-Piiq is typically given every three weeks, often in combination with other drugs.
• What should I do if I experience side effects?
  Report any side effects—especially severe or unusual symptoms—to your healthcare team promptly for evaluation and management.
• Can I get a cost estimate for the entire treatment course?
  Yes, request an itemized estimate from your provider that includes drug, administration, facility, and ancillary service costs.
• Will I need additional medications or tests?
  Yes, you may need supportive medications, blood tests, and periodic imaging to monitor your response and manage side effects.
• Is there support available for managing treatment logistics?
  Most cancer centers have nurse navigators or social workers who can help coordinate care, transportation, and support resources during treatment.

Polatuzumab Vedotin-Piiq is a targeted cancer therapy used in the treatment of certain types of lymphoma, specifically designed to deliver chemotherapy directly to cancer cells, thereby minimizing damage to healthy cells. At Aurora Medical Center in Sheboygan County, this intravenous solution is priced at $594.62 for a 140 milligram dose. This pricing reflects the cost of the medication itself and does not include additional fees that may be associated with administration or other medical services provided during treatment.

What is Polatuzumab Vedotin-Piiq used for? – Polatuzumab Vedotin-Piiq is primarily used for treating certain types of non-Hodgkin lymphoma, often in combination with other chemotherapy drugs, to target and destroy cancerous cells.

How is Polatuzumab Vedotin-Piiq administered? – This medication is administered intravenously, meaning it is given directly into a vein through an IV, typically in a clinical setting under the supervision of a healthcare professional.

What are the potential side effects of Polatuzumab Vedotin-Piiq? – Common side effects may include fatigue, nausea, diarrhea, and low blood cell counts, while more serious side effects can include nerve damage and infusion-related reactions.

How often is Polatuzumab Vedotin-Piiq given? – The frequency of administration depends on the specific treatment regimen prescribed by a healthcare provider, often given in cycles over several weeks.

Is Polatuzumab Vedotin-Piiq covered by insurance? – Coverage for this medication varies by insurance provider and plan, so it is important for patients to consult with their insurance company to determine their specific coverage and out-of-pocket costs.

Are there any special precautions to take while on Polatuzumab Vedotin-Piiq? – Patients should inform their healthcare provider of any other medications they are taking and any pre-existing health conditions, as well as report any unusual symptoms or side effects experienced during treatment.

Can Polatuzumab Vedotin-Piiq be used in combination with other treatments? – Yes, it is often used in combination with other chemotherapy agents to enhance its effectiveness in treating lymphoma, but this should be determined by a healthcare provider based on individual patient needs.